Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 4/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28116069 | 1.00 | KMT2A (0.52) | KMT2ASMN1; SMN2LTA4HLNPEPSIRT2 | |
| SCHEMBL14698090 | 0.85 | KMT2A (0.70) | KMT2ASMN1; SMN2LTA4HSIRT2SIRT3 | |
| SCHEMBL28116080 | 0.85 | KMT2A (0.70) | KMT2ASMN1; SMN2LTA4HSIRT2SIRT3 | |
| SCHEMBL7947624 | 0.84 | HDAC4 (0.33) | KMT2ASMN1; SMN2 | |
| SCHEMBL7947620 | 0.84 | HDAC4 (0.33) | KMT2ASMN1; SMN2 | |
| SCHEMBL25453027 | 0.82 | GGPS1 (0.35) | KMT2AALOX5PRKCD | |
| SCHEMBL3861123 | 0.81 | MKNK1 (0.37) | FFAR1 | |
| SCHEMBL3861120 | 0.81 | MKNK1 (0.37) | FFAR1 | |
| SCHEMBL30192558 | 0.77 | — | — | |
| SCHEMBL28116074 | 0.76 | PPARA (0.45) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| US-9744252-B2 | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2017-08-29 | — | — | US | disclosed |
| EP-2744802-B1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2017-01-04 | — | — | EP | disclosed |
| CN-103906743-B | The compound being combined with blood-platelet specific glycoprotein iib/iiia and the purposes of its thrombus imaging | 皮拉莫尔影像股份公司 | 2016-12-28 | — | — | CN | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9345793-B2 | Compounds for binding to the platelet specific glycoprotein IIB/IIIA and their use for imaging of thrombi | PIRAMAL IMAGING SA (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2016-05-19 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2014-10-23 | — | — | US | disclosed |
| WO-2013023795-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | PIRAMAL IMAGING SA (CH) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314669-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | KMT2A 4576/4885SMN1; SMN2 4795/4885LTA4H 1100/4885 |
| US-20160137629-A1 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIb/IIIa AND THEIR USE FOR IMAGING OF THROMBI | F13B, FGB, SELPLG | KMT2A 4576/4885SMN1; SMN2 4795/4885LTA4H 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.